My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 242

    1.

    Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

    Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E.

    Diabetes Care. 2005 May;28(5):1068-76.PMID: 15855569 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of insulin in relatives of patients with type 1 diabetes mellitus.

    Diabetes Prevention Trial--Type 1 Diabetes Study Group.

    N Engl J Med. 2002 May 30;346(22):1685-91.PMID: 12037147 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.

    Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG.

    Diabetologia. 1998 May;41(5):536-41.PMID: 9628270 [PubMed - indexed for MEDLINE]Related articles

    4.

    Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?

    Schatz D, Cuthbertson D, Atkinson M, Salzler MC, Winter W, Muir A, Silverstein J, Cook R, Maclaren N, She JX, Greenbaum C, Krischer J.

    Pediatr Diabetes. 2004 Jun;5(2):72-9.PMID: 15189492 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.

    Barker JM, McFann KK, Orban T.

    Diabetologia. 2007 Aug;50(8):1603-6. Epub 2007 Jun 22.PMID: 17583798 [PubMed - indexed for MEDLINE]Related articles

    6.

    Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

    Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O.

    Lancet. 2008 Nov 15;372(9651):1746-55. Epub 2008 Sep 22.PMID: 18814906 [PubMed - indexed for MEDLINE]Related articles

    7.

    Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the diabetes prevention trial-type 1 (DPT-1).

    Butty V, Campbell C, Mathis D, Benoist C; DPT-1 Study Group.

    Diabetes. 2008 Sep;57(9):2348-59. Epub 2008 Jun 12.PMID: 18556337 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effects of insulin administration in a group of high-risk, non-diabetic, first-degree relatives of Type 1 diabetic patients: an open pilot trial.

    Rodríguez-Villar C, Conget I, Casamitjana R, Ercilla G, Gomis R.

    Diabet Med. 1999 Feb;16(2):160-3.PMID: 10229311 [PubMed - indexed for MEDLINE]Related articles

    9.

    Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT).

    Bingley PJ, Mahon JL, Gale EA; European Nicotinamide Diabetes Intervention Trial Group.

    Diabetes Care. 2008 Jan;31(1):146-50. Epub 2007 Oct 24.PMID: 17959864 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1.

    Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS, Krischer JP; DPT-1 Participating Investigators.

    Diabetes. 2001 Aug;50(8):1735-40.PMID: 11473032 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

    Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2008 Mar;31(3):528-33. Epub 2007 Nov 13.PMID: 18000175 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk.

    Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group.

    Diabetologia. 2006 May;49(5):881-90. Epub 2006 Mar 3.PMID: 16514546 [PubMed - indexed for MEDLINE]Related articles

    13.

    Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).

    European Nicotinamide Diabetes Intervention Trial Group.

    Diabetologia. 2003 Mar;46(3):339-46. Epub 2003 Feb 27. Erratum in: Diabetologia. 2003 Sep;46(9):1296. PMID: 12687331 [PubMed - indexed for MEDLINE]Related articles

    14.

    Role of insulin resistance in predicting progression to type 1 diabetes.

    Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2007 Sep;30(9):2314-20. Epub 2007 May 29.PMID: 17536068 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Predictive value of age-related acute insulin response to glucose in subjects at risk for type 1 diabetes: results of a 6-year follow-up study from west-France.

    Bardet S, Joseph MG, Maugendre D, Matthieu E, Chaillous L, Semana G, Limal JM, Allannic H, Charbonnel B, Sai P.

    Diabete Metab. 1993 Jul-Aug;19(4):372-80. Erratum in: Diabete Metab 1993 Nov-Dec;19(6):602. PMID: 8293864 [PubMed - indexed for MEDLINE]Related articles

    16.

    No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

    Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crinò A, Spera S, Suraci C, Multari G, Cervoni M, Manca Bitti ML, Matteoli MC, Marietti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G.

    Diabetologia. 2000 Aug;43(8):1000-4.PMID: 10990077 [PubMed - indexed for MEDLINE]Related articles

    17.

    The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.

    Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H.

    Diabetes. 1998 Jun;47(6):980-4.PMID: 9604880 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes.

    Cabrera-Rode E, Molina G, Arranz C, Vera M, González P, Suárez R, Prieto M, Padrón S, León R, Tillan J, García I, Tiberti C, Rodríguez OM, Gutiérrez A, Fernández T, Govea A, Hernández J, Chiong D, Domínguez E, Di Mario U, Díaz-Díaz O, Díaz-Horta O.

    Autoimmunity. 2006 Jun;39(4):333-40.PMID: 16891222 [PubMed - indexed for MEDLINE]Related articles

    19.

    First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes.

    Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J.

    J Pediatr. 2001 Feb;138(2):244-9.PMID: 11174623 [PubMed - indexed for MEDLINE]Related articles

    20.

    Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.

    Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, Couper JJ, Colman PG.

    Diabetes Care. 2004 Oct;27(10):2348-55.PMID: 15451899 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity